Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

90.04EUR
5 May 2015
Change (% chg)

-- (--)
Prev Close
€90.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,112,326
52-wk High
€99.23
52-wk Low
€69.58

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.62
Market Cap(Mil.): €122,380.60
Shares Outstanding(Mil.): 1,326.24
Dividend: 2.85
Yield (%): 3.09

Financials

  SASY.PA Industry Sector
P/E (TTM): 28.13 39.67 40.78
EPS (TTM): 3.28 -- --
ROI: 5.49 16.22 15.61
ROE: 7.77 16.75 16.45
Search Stocks

UPDATE 1-Sanofi rebels make mark in AGM vote on CEO pay

* Large shareholder minority votes against the pay packages (Adds detail on packages)

04 May 2015

Sanofi rebels make mark in AGM vote on CEO pay

PARIS, May 4 - Shareholders in drugs group Sanofi , which sacked its chief executive last year and appointed a new one in February, approved millions of euros in payments to both men on Monday despite a substantial rebellion by activist investors.

04 May 2015

RPT-Sanofi faces AGM row over cost of firing and hiring CEOs

PARIS, April 30 - Drugs group Sanofi, which sacked its chief executive last year and appointed a new one in February, has appealed for shareholder loyalty as it seeks to head off a potential rebellion over millions of euros in payments to both men.

01 May 2015

Sanofi faces AGM row over cost of firing and hiring CEOs

PARIS, April 30 - Drugs group Sanofi, which sacked its chief executive last year and appointed a new one in February, has appealed for shareholder loyalty as it seeks to head off a potential rebellion over millions of euros in payments to both men.

01 May 2015

CORRECTED-UPDATE 2-Sanofi warns of lower diabetes drug sales this year

PARIS, April 30 - France's Sanofi warned revenue in its key diabetes division would fall this year after it was forced to offer discounts for its best-selling drug Lantus in the United States.

30 Apr 2015

Sanofi keeps 2015 guidance with steady Q1 profits

PARIS, April 30 - Drugs firm Sanofi maintained its guidance for stable to slightly growing 2015 profit on Thursday as first-quarter earnings grew modestly and beat expectations despite declining sales of its main drug Lantus.

30 Apr 2015

BRIEF-Ypsomed to increase production capacity for new project with Sanofi

* Long-standing partnership between the French pharmaceutical group Sanofi and the Ypsomed Group will be bolstered by new major project

24 Apr 2015

BRIEF-Sanofi to present new data from Lemtrada clinical development

* Says effect of Genzyme's multiple sclerosis treatment Lemtrada (alemtuzumab) on slowing brain atrophy and MRI lesion activity has been maintained through four years

23 Apr 2015

BRIEF-Innate Pharma and Sanofi collaborate on antibody-drug conjugates

* Innate Pharma and Sanofi SA collaborate on next generation antibody-drug conjugates

16 Apr 2015

BRIEF-Delta Plus Group acquires 50 pct of North American Elvex

* Announces the signing of a strategic partnership on the North American market with Elvex

08 Apr 2015

Earnings vs. Estimates

Search Stocks